Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/168395
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | González-Gascón y Marín, Isabel | - |
dc.contributor.author | Hernández-Sánchez, María | - |
dc.contributor.author | Rodríguez-Vicente, Ana Eugenia | - |
dc.contributor.author | Sanzo, Carmen | - |
dc.contributor.author | Aventín, Anna | - |
dc.contributor.author | Puiggros, Anna | - |
dc.contributor.author | Collado, Rosa | - |
dc.contributor.author | Heras, Cecilia | - |
dc.contributor.author | Muñoz-Novas, Carolina | - |
dc.contributor.author | Delgado, Julio | - |
dc.contributor.author | Ortega, Margarita | - |
dc.contributor.author | González, María-Teresa | - |
dc.contributor.author | Marugán, Isabel | - |
dc.contributor.author | Fuente, Ignacio de la | - |
dc.contributor.author | Recio, Isabel | - |
dc.contributor.author | Bosch, Francesc | - |
dc.contributor.author | Espinet, Blanca | - |
dc.contributor.author | González, Marcos | - |
dc.contributor.author | Hernández, Jesús M. | - |
dc.contributor.author | Hernández, José Ángel | - |
dc.date.accessioned | 2018-08-07T12:16:50Z | - |
dc.date.available | 2018-08-07T12:16:50Z | - |
dc.date.issued | 2016 | - |
dc.identifier | doi: 10.1002/hon.2196 | - |
dc.identifier | e-issn: 1099-1069 | - |
dc.identifier | issn: 0278-0232 | - |
dc.identifier.citation | Hematological Oncology 34(2): 84-92 (2016) | - |
dc.identifier.uri | http://hdl.handle.net/10261/168395 | - |
dc.description | On behalf of Grupo Español de Leucemia Linfática Crónica (GELLC), Grupo Cooperativo Español de Citogenética Hematológica (GCECGH). | - |
dc.description.abstract | The prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129 months. One hundred seventy-four patients (60.2%) presented +12 in <60% of cells. TTFT and OS for this subgroup were longer than for the subgroup with +12 in ≥60% of cells, with a median TTFT of 49 months (CI95%, 39–58) vs 30 months (CI95%, 22–38) (P = 0.001); and a median OS of 159 months (CI95%, 119–182), vs 96 months (CI95%, 58–134) (P = 0.015). Other factors associated with a shorter TTFT were: Binet stage, B symptoms, lymphadenopathy, splenomegaly, high lymphocyte count, 11q-, high βmicroglobulin, and high LDH. In the multivariate analysis, clinical stage, +12 in ≥60% of cells, high lymphocyte count, B symptoms, and 11q- in addition, resulted of significance in predicting shorter TTFT. Significant variables for OS were: Binet stage, lymphadenopathy, splenomegaly, high LDH, high βmicroglobulin, 11q-, and CD38. In the multivariate analysis, only Binet stage, 11q-, and high β2microglobulin significantly predicted shorter OS. CLL with +12 entails a heterogeneous group with intermediate prognosis. However, a high proportion of cells carrying +12 separates a subgroup of patients with poor outcome. | - |
dc.description.sponsorship | This work was partially supported by grants from the Spanish Fondo de Investigaciones Sanitarias FIS 09/01543, PI12/00281, Proyectos de Investigación del SACYL 355/A/09, COST Action EuGESMA (BM0801), Fundación Manuel Solórzano, Obra Social Banca Cívica (Caja Burgos), Fundación Española de Hematología y Hemoterapia (FEHH), and by a grant (RD12/0036/0069) from Red Temática de Investigación Cooperativa en Cáncer (RTICC), Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness, and European Regional Development Fund (ERDF) “Una manera de hacer Europa” and IRON-II collaborative network. The research leading to these results has received funding from the European Union Seventh Framework Programme [FP7/2007-2013] under Grant Agreement no. 306242-NGS-PTL. María HernándezSánchez is fully supported by an Ayuda Predoctoral de la Junta de Castilla y León from the Fondo Social Europeo. | - |
dc.publisher | John Wiley & Sons | - |
dc.relation | info:eu-repo/grantAgreement/EC/FP7/306242 | - |
dc.rights | closedAccess | - |
dc.subject | Chronic lymphocytic leukemia | - |
dc.subject | Prognosis | - |
dc.title | A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia | - |
dc.type | artículo | - |
dc.identifier.doi | 10.1002/hon.2196 | - |
dc.date.updated | 2018-08-07T12:16:50Z | - |
dc.description.version | Peer Reviewed | - |
dc.language.rfc3066 | eng | - |
dc.contributor.funder | European Commission | - |
dc.contributor.funder | Instituto de Salud Carlos III | - |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | - |
dc.contributor.funder | Fundación Caja de Burgos | - |
dc.contributor.funder | Junta de Castilla y León | - |
dc.contributor.funder | Sociedad Española de Hematología y Hemoterapia | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100008782 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100003329 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100014180 | es_ES |
dc.identifier.pmid | 25689772 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
11
checked on 12-mar-2024
SCOPUSTM
Citations
25
checked on 19-abr-2024
WEB OF SCIENCETM
Citations
21
checked on 23-feb-2024
Page view(s)
357
checked on 23-abr-2024
Download(s)
90
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.